October 14, 2025 | As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocking new possibilities for complex format development, and shares a glimpse into Apoha’s future-including an exclusive preview of what’s coming at PEGS Europe this November.
GUEST BIO
Shamit Shrivastava, Ph.D., Founder and CEO of Apoha
Dr. Shamit Shrivastava is a mechanical engineer and biophysicist, known for his pioneering work on the thermodynamic theory of nerve pulse propagation. His research focuses on nonlinear acoustic waves and their role in signal transmission within biological systems. As co-founder and CEO of Apoha, a deep tech company, Shamit has transformed his scientific insights into a revolutionary computing platform called the "liquid brain," applying physical reservoir computing to solve critical challenges like antibody developability. His vision is centered on translating his fundamental discoveries on dynamic properties of soft materials into foundational technologies that tackle seemingly impossible problems in biophysics and material discovery. Shamit holds a Ph.D. in Bioengineering and Biomedical Engineering from Boston University and completed his post-doctoral training at Oxford University.
MODERATOR BIO
Nimish Gera, Ph.D., Vice President of Biologics, Mythic Therapeutics
Nimish Gera is the vice president of biologics at Mythic Therapeutics leading multiple projects to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over 15 years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology, and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and